Targeting A549 lung adenocarcinoma cell growth and invasion with protease‑activated receptor‑1 siRNA

Wu,Zhuo; Zeng,Yanyan; Zhong,Mingkang; Wang,Bin

doi:10.3892/mmr.2014.2023

Targeting A549 lung adenocarcinoma cell growth and invasion with protease‑activated receptor‑1 siRNA

Authors:
- Zhuo Wu
- Yanyan Zeng
- Mingkang Zhong
- Bin Wang
View Affiliations

Affiliations: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Pharmacy, Teaching Hospital of Fujian Medical University, Quanzhou Women's and Children's Hospital, Quanzhou, Fujian 362000, P.R. China
Published online on: March 6, 2014 https://doi.org/10.3892/mmr.2014.2023
Pages: 1787-1793

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the major cause of cancer‑associated mortality worldwide and the invasive and metastatic characteristics of lung tumor cells are responsible for their high malignancy. Protease‑activated receptor 1 (PAR1) is a G‑protein‑coupled receptor (GPCR) which is activated by a unique proteolytic mechanism. PARs have crucial roles in hemostasis and thrombosis as well as tumor progression. RNA interference (RNAi) is a fundamental cellular mechanism for gene silencing that is able to be harnessed for the development of novel anti‑cancer drugs. In the present study, PAR1 was successfully inhibited by using Lipofectamine RNAiMAX transfection reagent to deliver siRNA. Inhibition occurred at the mRNA and protein level as determined by polymerase chain reaction and western blot analysis. Furthermore, the growth and invasion of tumor cells were significantly decreased. In conclusion, the present study demonstrated that the progression of A549 cells is able to be inhibited by knockdown of PAR1 expression. Efficient delivery of the specific siRNA targeting PAR1 may be used for further study in clinical cancer therapy.

View Figures

View References

1	Wang Y, Yang H, Liu H, Huang J and Song X: Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer. 9:1742009. View Article : Google Scholar : PubMed/NCBI
2	Arora P, Ricks TK and Trejo J: Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci. 120:921–928. 2007. View Article : Google Scholar : PubMed/NCBI
3	Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pagès G, Pavirani A, Lecocq JP, Pouysségur J and Van Obberghen-Schilling E: cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca²⁺ mobilization. FEBS Lett. 288:123–128. 1991. View Article : Google Scholar : PubMed/NCBI
4	Vu TK, Hung DT, Wheaton VI and Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1057–1068. 1991. View Article : Google Scholar : PubMed/NCBI
5	Villares GJ, Zigler M, Wang H, et al: Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 68:9078–9086. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tellez C and Bar-Eli M: Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene. 22:3130–3137. 2003. View Article : Google Scholar : PubMed/NCBI
7	Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH and Pienta KJ: A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology. 60:760–765. 2002. View Article : Google Scholar : PubMed/NCBI
8	Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and Bar-Shavit R: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 4:909–914. 1998. View Article : Google Scholar : PubMed/NCBI
9	Darmoul D, Gratio V, Devaud H, Lehy T and Laburthe M: Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol. 162:1503–1513. 2003. View Article : Google Scholar : PubMed/NCBI
10	Zhang Y, Zhan H, Xu W, Yuan Z, Lu P, Zhan L and Li Q: Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas. Pathol Res Pract. 207:24–29. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hernández NA, Correa E, Avila EP, Vela TA and Pérez VM: PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study. J Transl Med. 7:472009.PubMed/NCBI
12	Du X, Wang S, Lu J, et al: Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. Jpn J Clin Oncol. 41:1086–1093. 2011. View Article : Google Scholar : PubMed/NCBI
13	Bar-Shavit R, Turm H, Salah Z, Maoz M, Cohen I, Weiss E, Uziely B and Grisaru-Granovsky S: PAR1 plays a role in epithelial malignancies: transcriptional regulation and novel signaling pathway. IUBMB Life. 63:397–402. 2011. View Article : Google Scholar : PubMed/NCBI
14	Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA and Pienta KJ: PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem. 96:641–652. 2005. View Article : Google Scholar : PubMed/NCBI
15	Shimizu S, Gabazza EC, Hayashi T, Ido M, Adachi Y and Suzuki K: Thrombin stimulates the expression of PDGF in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 279:L503–L510. 2000.PubMed/NCBI
16	Huang YQ, Li JJ, Hu L, Lee M and Karpatkin S: Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost. 86:1094–1098. 2001.PubMed/NCBI
17	Boire A, Covic L, Agarwal A, Jacques S, Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 120:303–313. 2005. View Article : Google Scholar : PubMed/NCBI
18	Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J and Leffall LD: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med. 11:481–483. 2005. View Article : Google Scholar : PubMed/NCBI
19	Murray GI, Duncan ME, O’Neil P, McKay JA, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 185:256–261. 1998. View Article : Google Scholar : PubMed/NCBI
20	Migita T, Sato E, Saito K, Mizoi T, Shiiba K, Matsuno S, Nagura H and Ohtani H: Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Int J Cancer. 84:74–79. 1999. View Article : Google Scholar : PubMed/NCBI
21	Yang E, Boire A, Agarwal A, Nguyen N, O’Callaghan K, Tu P, Kuliopulos A and Covic L: Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 69:6223–6231. 2009. View Article : Google Scholar : PubMed/NCBI
22	Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng. 23:17–34. 2006. View Article : Google Scholar
23	Kim DH and Rossi JJ: Overview of gene silencing by RNA interference. Curr Protoc Nucleic Acid Chem. Beaucage SL: 16(Unit 16.1)Wiley; New York, NY: 2009, View Article : Google Scholar
24	Takeshita F and Ochiya T: Therapeutic potential of RNA interference against cancer. Cancer Sci. 97:689–696. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, Liu H and Xiao H: In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol. 108:177–184. 2011. View Article : Google Scholar : PubMed/NCBI
26	Xiao H, Wu Z, Shen H, Luo AL, Yang YF, Li XB and Zhu DY: In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin Pharmacol Toxicol. 103:342–348. 2008. View Article : Google Scholar : PubMed/NCBI
27	Perrimon N, Ni JQ and Perkins L: In vivo RNAi: today and tomorrow. Cold Spring Harb Perspect Biol. 2:a0036402010. View Article : Google Scholar : PubMed/NCBI
28	Seyhan AA: RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet. 130:583–605. 2011. View Article : Google Scholar : PubMed/NCBI
29	Heller LC, Ugen K and Heller R: Electroporation for targeted gene transfer. Expert Opin Drug Deliv. 2:255–268. 2005. View Article : Google Scholar : PubMed/NCBI
30	Li S: Electroporation gene therapy: new developments in vivo and in vitro. Curr Gene Ther. 4:309–316. 2004. View Article : Google Scholar : PubMed/NCBI
31	Wells DJ: Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 11:1363–1369. 2004. View Article : Google Scholar : PubMed/NCBI